Ileus News and Research

RSS

Ileus or gastrointestinal atony is a disruption of the normal propulsive gastrointestinal motor activity due to non-mechanical causes.

New campaign aims to reduce missed or delayed diagnosis of cystic fibrosis after newborn screening

Ann & Robert H. Lurie Children's Hospital of Chicago is leading an awareness campaign that aims to reduce missed or delayed diagnosis of cystic fibrosis after newborn screening, especially in non-White infants.

24 Jul 2023

Mental health profoundly impacts inflammatory responses in the body

Study uncovered mechanisms by which psychological stress affects bowel inflammation.

30 May 2023

New hot-melt tissue adhesive can heal operative wounds

NIMS has developed a hot-melt tissue adhesive (i.e., medical glue that is applied in a molten state) capable of healing operative wounds.

9 Jun 2022

Chewing gum after cardiac surgery may accelerate the return of gut function

Chewing gum after heart surgery may kickstart the digestive tract, helping patients feel better and potentially be discharged sooner than those who don't use this generally safe and simple intervention, according to research presented today at the 18th Annual Perioperative and Critical Care Conference from The Society of Thoracic Surgeons.

10 Sep 2021

Large-scale enhanced recovery program after bariatric surgery improves patient outcomes

A large-scale implementation of a protocol to improve recovery of patients after weight-loss operations was found to reduce rates of extended hospitalization by almost half at 36 participating accredited bariatric surgery centers nationwide, according to a study published online ahead of print in the current issue of the journal Surgery for Obesity and Related Diseases.

24 Sep 2019

Coffee intake after elective laparoscopic colorectal surgery leads to faster recovery of bowel function

Researchers from Switzerland evaluated the effect of standardized coffee intake on postoperative bowel movement after elective laparoscopic colorectal resection. This was a prospective randomized controlled trial conducted between September 2014 and December 2016.

31 Jul 2019

Coffee helps develop healthy gut microbes and aids bowel movements

There has been anecdotal evidence that coffee drinkers swear by their morning cup for normal morning bowel movements. A new study from researchers in Texas has shown that coffee indeed helps in bowel movements and also improves the gut microbe population.

20 May 2019

Researchers examine how coffee helps bowel movement

Coffee drinkers know that coffee helps keep the bowels moving, but researchers in Texas are trying to find out exactly why this is true, and it doesn't seem to be about the caffeine, according to a study presented at Digestive Disease Week® 2019.

20 May 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Researchers show that separate septic and aseptic procedure rooms is unnecessary

In Germany, the rule still applies that aseptic and septic and procedure rooms need to be separate; this is a requirement imposed by the Accident Insurance Provider for Hospitals.

8 Sep 2017

KU Leuven research reveals mechanism behind post-operative ileus

In the days following abdominal surgery, patients' intestinal contents pass more slowly or not at all. New research at KU Leuven, Belgium, has now shown that this phenomenon -- known as post-operative ileus or bowel paralysis -- is not caused by the cells previously identified as the main players.

20 Jun 2017

ESCMID releases new guidelines on best practices to detect C. difficile infections

The European Society of Clinical Microbiology and Infectious Diseases has just released new guidelines on best practice methods to diagnose Clostridium difficile infection (CDI).

26 Aug 2016

Study finds that ACS NSQIP Surgical Risk Calculator has excellent calibration

The American College of Surgeons National Surgical Quality Improvement Program Surgical Risk Calculator accurately estimates the chance of a patient experiencing postoperative complications, and its performance can improve with recalibration of the tool according to research findings appearing online in the Journal of the American College of Surgeons in advance of print publication.

20 May 2016

Human-gut-on-a-chip model offers hope for patients suffering from IBD

It's estimated that as many as 1,000,000 Americans suffer from inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, which cause mild to severe symptoms that at best can be managed and at worst can lead to life-threatening complications.

16 Dec 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015